Signal Neuralink Expands Human Trials to 21 Participants — VOICE Trial Targets 140 Words/min

Summary

Neuralink has 21 trial participants across the United States, Canada, the United Kingdom and the United Arab Emirates. Its VOICE trial targets real-time speech restoration at around 140 words per minute. Patients enrolled since 2024 have played Mario Kart and Call of Duty and operated CAD software by thought alone. Human trials of Blindsight, a vision-restoration brain implant designated an FDA breakthrough device, begin in 2026. The thread retraction problem identified earlier has been resolved, and the trial programme has expanded internationally.